Choose a language and wait for the translated text.
Shots:
China’s NMPA has accepted the IND application for Harbour BioMed’s LET003, a next-gen ACVR2A/2B-targeting mAb developed using its Hu-mAtrIx AI platform, for the treatment of overweight or obesity
LET003 is Harbour BioMed’s first AI-enabled drug candidate, designed as a dual ACVR2A/ACVR2B blocker to enhance fat reduction while preserving or improving lean mass, particularly in combination with existing weight-loss therapies
In preclinical studies, LET003 showed superior PK vs multiple competitor molecules, enhanced fat reduction while preserving lean mass in combination with semaglutide & achieved lean mass-promoting effects at a lower dose comparable to bimagrumab at a higher dose
Ref: PR Newswire | Image: Harbour BioMed | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post The NMPA Accepts Harbour BioMed’s IND Application for AI-Enabled LET003 to Treat Overweight or Obesity appeared first on PharmaShots.